BioXcel Therapeutics (NASDAQ: BTAI) grants 1,353,729 low-price warrants
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
BioXcel Therapeutics, Inc. entered into a Ninth Amendment to its Credit Agreement and Guaranty and, on April 15, 2026, granted the lenders warrants to purchase up to 1,353,729 shares of common stock at an exercise price of $0.01 per share. These Amendment Warrants expire on the seventh anniversary of issuance.
On April 15, 2026, BioXcel also signed a Fourth Amended and Restated Registration Rights Agreement with the lenders, under which it agreed to register the common shares issuable upon exercise of the Amendment Warrants. The securities were issued in a private transaction relying on Section 4(a)(2) of the Securities Act.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 3.02, 9.01
2 items
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Warrant share amount: 1,353,729 shares
Warrant exercise price: $0.01 per share
Warrant term: Seven years
+3 more
6 metrics
Warrant share amount
1,353,729 shares
Maximum common shares purchasable under Amendment Warrants
Warrant exercise price
$0.01 per share
Exercise price for Amendment Warrants granted to lenders
Warrant term
Seven years
Expiration is on the seventh anniversary of issuance
Credit Agreement date
April 19, 2022
Original Credit Agreement and Guaranty date
Ninth Amendment date
March 27, 2026
Date BioXcel entered into Ninth Amendment
Warrant issuance date
April 15, 2026
Date Amendment Warrants were granted to lenders
Key Terms
Ninth Amendment to the Credit Agreement and Guaranty, Amendment Warrants, Fourth Amended and Restated Registration Rights Agreement, Section 4(a)(2) of the Securities Act, +1 more
5 terms
Ninth Amendment to the Credit Agreement and Guaranty financial
"On March 27, 2026, BioXcel Therapeutics, Inc. entered into the Ninth Amendment to the Credit Agreement and Guaranty, dated April 19, 2022"
Amendment Warrants financial
"the Company granted the lenders under the Ninth Amendment warrants to purchase up to 1,353,729 shares of common stock at an exercise price of $0.01 per share (the “Amendment Warrants”)"
Fourth Amended and Restated Registration Rights Agreement financial
"the Company also entered into the Fourth Amended and Restated Registration Rights Agreement with the Lenders"
Section 4(a)(2) of the Securities Act regulatory
"in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended, contained in Section 4(a)(2) of the Securities Act"
A legal exemption that allows a company to sell securities directly to a limited group of buyers without registering the offering with the Securities and Exchange Commission. Think of it like a private sale among known parties rather than a public auction: it can speed fundraising and reduce disclosure requirements, but it also means less public information, lower liquidity and resale restrictions—factors investors should consider when weighing risk and exit options.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did BioXcel Therapeutics (BTAI) announce in this Form 8-K?
BioXcel Therapeutics reported a Ninth Amendment to its Credit Agreement and granted lenders warrants to buy up to 1,353,729 common shares at $0.01 per share, along with updated registration rights for those warrant shares.
How many warrants did BioXcel Therapeutics (BTAI) issue to its lenders?
The company issued warrants to purchase up to 1,353,729 shares of common stock. These Amendment Warrants were granted to the lenders under the Ninth Amendment to the Credit Agreement and carry a very low exercise price of $0.01 per share.
What is the exercise price and term of BioXcel’s new warrants?
Each Amendment Warrant allows the holder to purchase common stock at an exercise price of $0.01 per share. The warrants will remain outstanding until the seventh anniversary of their issuance date, giving lenders a long exercise window.
Were BioXcel’s new warrants issued in a public offering?
No. The Amendment Warrants and the shares issuable upon their exercise were issued in a private transaction. BioXcel relied on the exemption from registration in Section 4(a)(2) of the Securities Act, with lenders stating they are acquiring the securities for investment only.
Who are the main counterparties in BioXcel’s amended registration rights agreement?
The Fourth Amended and Restated Registration Rights Agreement is among BioXcel Therapeutics and multiple lender entities, including various Oaktree-affiliated funds, INPRS Strategic Credit Holdings, Oaktree Specialty Lending Corporation, and Q Boost Holding LLC, among others listed in Exhibit 4.2.